Gilberto Lopes
Gilberto Lopes
Sylvester Comprehensive Cancer Center at the University of Miami
Verified email at - Homepage
Cited by
Cited by
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
Planning cancer control in Latin America and the Caribbean
PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ...
The lancet oncology 14 (5), 391-436, 2013
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE …
N Thatcher, FR Hirsch, AV Luft, A Szczesna, TE Ciuleanu, M Dediu, ...
The lancet oncology 16 (7), 763-774, 2015
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ...
The lancet oncology 22 (7), 959-969, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ...
The lancet Diabetes & endocrinology 9 (8), 491-501, 2021
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥ 1%: open-label …
G Lopes, YL Wu, I Kudaba, D Kowalski, BC Cho, G Castro, ...
Journal of Clinical Oncology 36 (18_suppl), LBA4-LBA4, 2018
Early detection for colorectal cancer: ASCO resource-stratified guideline
G Lopes, MC Stern, S Temin, AI Sharara, A Cervantes, A Costas-Chavarri, ...
Journal of global oncology 5, 1-22, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024 …
K Nosaki, H Saka, Y Hosomi, P Baas, G de Castro Jr, M Reck, YL Wu, ...
Lung Cancer 135, 188-195, 2019
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
PN Aguiar Jr, RA De Mello, P Hall, H Tadokoro, G Lima Lopes
Immunotherapy 9 (6), 499-506, 2017
Progress and remaining challenges for cancer control in Latin America and the Caribbean
K Strasser-Weippl, Y Chavarri-Guerra, C Villarreal-Garza, BL Bychkovsky, ...
The lancet oncology 16 (14), 1405-1438, 2015
Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries
JA De Souza, B Hunt, FC Asirwa, C Adebamowo, G Lopes
Journal of Clinical Oncology 34 (1), 6, 2016
How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years
KK Tan, G de Lima Lopes Jr, R Sim
Journal of gastrointestinal surgery 13 (4), 642-648, 2009
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ...
JAMA oncology 7 (8), 1167-1175, 2021
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
PN Aguiar Jr, IL Santoro, H Tadokoro, G de Lima Lopes, BA Filardi, ...
Immunotherapy 8 (4), 479-488, 2016
Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature
JA Chirinos, LJ Tamariz, G Lopes, F Del Carpio, X Zhang, C Milikowski, ...
Clinical rheumatology 23, 152-159, 2004
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study
DR Rivera, S Peters, OA Panagiotou, DP Shah, NM Kuderer, CY Hsu, ...
Cancer discovery 10 (10), 1514-1527, 2020
A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer
PJ Hosein, G de Lima Lopes Jr, VH Pastorini, C Gomez, J Macintyre, ...
American Journal of Clinical Oncology, 2012
Lung cancer in Brazil
LH Araujo, C Baldotto, G Castro Jr, A Katz, CG Ferreira, C Mathias, ...
Jornal Brasileiro de Pneumologia 44, 55-64, 2018
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-Fusion+ non small cell lung cancer
JF Gainor, DH Lee, G Curigliano, RC Doebele, DW Kim, CS Baik
J Clin Oncol 37 (15 suppl), 9008, 2019
The system can't perform the operation now. Try again later.
Articles 1–20